Bio-Rad Laboratories, Inc. (NYSE: BIO) Stock Competitors & Peer Comparison

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO's ROE is +0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BIO is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BSX-PA's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ABT trades at $100.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ABT's P/E ratio is 19.38. In terms of profitability, BIO's ROE is +0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ABT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while MDT trades at $89.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas MDT's P/E ratio is 16.18. In terms of profitability, BIO's ROE is +0.03%, compared to MDT's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MDT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SYK trades at $275.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SYK's P/E ratio is 20.57. In terms of profitability, BIO's ROE is +0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BIO is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SYK's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BSX trades at $44.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BSX's P/E ratio is 14.23. In terms of profitability, BIO's ROE is +0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BIO is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check BSX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, EW has a market cap of 50B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while EW trades at $86.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas EW's P/E ratio is 32.16. In terms of profitability, BIO's ROE is +0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BIO.Check EW's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while DXCM trades at $86.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas DXCM's P/E ratio is 33.99. In terms of profitability, BIO's ROE is +0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BIO is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for BIO.Check DXCM's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while GEHC trades at $66.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas GEHC's P/E ratio is 14.64. In terms of profitability, BIO's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, BIO is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for BIO.Check GEHC's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PHG trades at $25.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PHG's P/E ratio is 14.35. In terms of profitability, BIO's ROE is +0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BIO.Check PHG's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ZBH trades at $91.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ZBH's P/E ratio is 10.80. In terms of profitability, BIO's ROE is +0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ZBH's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ABMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PEN trades at $319.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PEN's P/E ratio is 83.31. In terms of profitability, BIO's ROE is +0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check PEN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO's ROE is +0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SWAV's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SNN trades at $27.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SNN's P/E ratio is 18.28. In terms of profitability, BIO's ROE is +0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SNN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, BIO's ROE is +0.03%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, BIO is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BIO.Check BIO-B's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ALGN trades at $145.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ALGN's P/E ratio is 13.22. In terms of profitability, BIO's ROE is +0.03%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BIO is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ALGN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while GMED trades at $74.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas GMED's P/E ratio is 16.84. In terms of profitability, BIO's ROE is +0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BIO.Check GMED's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BRKR trades at $63.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BRKR's P/E ratio is 31.80. In terms of profitability, BIO's ROE is +0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BIO is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BRKR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas MASI's P/E ratio is 44.43. In terms of profitability, BIO's ROE is +0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BIO is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MASI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, GKOS has a market cap of 9.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while GKOS trades at $158.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas GKOS's P/E ratio is -184.31. In terms of profitability, BIO's ROE is +0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BIO is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check GKOS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BRKRP trades at $469.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, BIO's ROE is +0.03%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, BIO is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for BIO.Check BRKRP's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PODD trades at $133.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PODD's P/E ratio is 22.68. In terms of profitability, BIO's ROE is +0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BIO is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PODD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while HAE trades at $105.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas HAE's P/E ratio is 21.13. In terms of profitability, BIO's ROE is +0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for BIO.Check HAE's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO's ROE is +0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BIO.Check NARI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ITGR trades at $126.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ITGR's P/E ratio is 19.90. In terms of profitability, BIO's ROE is +0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BIO is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ITGR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while LIVN trades at $77.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas LIVN's P/E ratio is 18.34. In terms of profitability, BIO's ROE is +0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BIO is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LIVN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while IRTC trades at $112.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas IRTC's P/E ratio is -261.86. In terms of profitability, BIO's ROE is +0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BIO is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BIO.Check IRTC's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIO's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check AXNX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NEOG trades at $13.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NEOG's P/E ratio is 49.00. In terms of profitability, BIO's ROE is +0.03%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, BIO is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NEOG's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while TMDX trades at $82.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas TMDX's P/E ratio is 41.99. In terms of profitability, BIO's ROE is +0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BIO is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TMDX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BFLY trades at $9.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BFLY's P/E ratio is -38.10. In terms of profitability, BIO's ROE is +0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BIO is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BFLY's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AXGN trades at $43.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AXGN's P/E ratio is 114.11. In terms of profitability, BIO's ROE is +0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BIO is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AXGN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while UFPT trades at $299.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas UFPT's P/E ratio is 30.56. In terms of profitability, BIO's ROE is +0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check UFPT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NUVA's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while INSP trades at $70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas INSP's P/E ratio is 30.84. In terms of profitability, BIO's ROE is +0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BIO is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for BIO.Check INSP's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ESTA trades at $65.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ESTA's P/E ratio is -51.86. In terms of profitability, BIO's ROE is +0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BIO is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ESTA's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NVCR trades at $15.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NVCR's P/E ratio is -12.18. In terms of profitability, BIO's ROE is +0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BIO is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NVCR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ATEC trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ATEC's P/E ratio is -167.50. In terms of profitability, BIO's ROE is +0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BIO is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ATEC's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CNMD trades at $46.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CNMD's P/E ratio is 10.20. In terms of profitability, BIO's ROE is +0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BIO is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CNMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BIO.Check HSKA's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while IART trades at $16.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas IART's P/E ratio is 6.89. In terms of profitability, BIO's ROE is +0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for BIO.Check IART's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BIO's ROE is +0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BIO.Check AVNS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while TNDM trades at $16.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas TNDM's P/E ratio is -17.66. In terms of profitability, BIO's ROE is +0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BIO is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TNDM's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO's ROE is +0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SILK's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AORT trades at $22.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AORT's P/E ratio is 38.23. In terms of profitability, BIO's ROE is +0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BIO is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AORT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while IRMD trades at $86.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas IRMD's P/E ratio is 43.55. In terms of profitability, BIO's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check IRMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO's ROE is +0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BIO is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BIO.Check FNA's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ENOV trades at $18.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ENOV's P/E ratio is 5.20. In terms of profitability, BIO's ROE is +0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BIO is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ENOV's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PRCT trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PRCT's P/E ratio is -8.89. In terms of profitability, BIO's ROE is +0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BIO is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PRCT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while LMRI trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas LMRI's P/E ratio is -19.74. In terms of profitability, BIO's ROE is +0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BIO is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LMRI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BVS trades at $14.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BVS's P/E ratio is 18.45. In terms of profitability, BIO's ROE is +0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BIO is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BVS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CBLL trades at $24.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CBLL's P/E ratio is -13.93. In terms of profitability, BIO's ROE is +0.03%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BIO is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CBLL's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BBNX trades at $20.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BBNX's P/E ratio is -12.44. In terms of profitability, BIO's ROE is +0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BIO is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BBNX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BIO.Check CSII's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SIBN trades at $18.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SIBN's P/E ratio is -55.18. In terms of profitability, BIO's ROE is +0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BIO is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SIBN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while INMD trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas INMD's P/E ratio is 9.86. In terms of profitability, BIO's ROE is +0.03%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BIO is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check INMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while VREX trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas VREX's P/E ratio is 19.43. In terms of profitability, BIO's ROE is +0.03%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BIO is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check VREX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AHCO trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AHCO's P/E ratio is 11.53. In terms of profitability, BIO's ROE is +0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BIO is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BIO.Check AHCO's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while AVR trades at $7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas AVR's P/E ratio is -3.99. In terms of profitability, BIO's ROE is +0.03%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BIO is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for BIO.Check AVR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CTKB trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CTKB's P/E ratio is -30.41. In terms of profitability, BIO's ROE is +0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BIO is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CTKB's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO's ROE is +0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BIO is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SRDX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while KIDS trades at $22.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas KIDS's P/E ratio is -19.14. In terms of profitability, BIO's ROE is +0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BIO is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for BIO.Check KIDS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BIO.Check APEN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SSII trades at $2.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SSII's P/E ratio is -48.17. In terms of profitability, BIO's ROE is +0.03%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BIO is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SSII's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while DCTH trades at $15.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, BIO's ROE is +0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BIO is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BIO.Check DCTH's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO's ROE is +0.03%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, BIO is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ZIMV's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PACB trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PACB's P/E ratio is -4.17. In terms of profitability, BIO's ROE is +0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BIO is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PACB's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while TCMD trades at $22.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas TCMD's P/E ratio is 21.13. In terms of profitability, BIO's ROE is +0.03%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BIO is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check TCMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SGHT trades at $9.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SGHT's P/E ratio is -16.55. In terms of profitability, BIO's ROE is +0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BIO is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SGHT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CERS trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CERS's P/E ratio is -81.40. In terms of profitability, BIO's ROE is +0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BIO is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CERS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NPCE trades at $14.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NPCE's P/E ratio is -24.82. In terms of profitability, BIO's ROE is +0.03%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BIO is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BIO.Check NPCE's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CLPT trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CLPT's P/E ratio is -12.97. In terms of profitability, BIO's ROE is +0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BIO is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CLPT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SENS trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SENS's P/E ratio is -4.41. In terms of profitability, BIO's ROE is +0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BIO is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check SENS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while OFIX trades at $9.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas OFIX's P/E ratio is -6.41. In terms of profitability, BIO's ROE is +0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BIO is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check OFIX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CV trades at $6.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CV's P/E ratio is -10.98. In terms of profitability, BIO's ROE is +0.03%, compared to CV's ROE of -1.78%. Regarding short-term risk, BIO is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CV's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO's ROE is +0.03%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, BIO is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BIO.Check SMLR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while TMCI trades at $4.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas TMCI's P/E ratio is -4.77. In terms of profitability, BIO's ROE is +0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BIO is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for BIO.Check TMCI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while RCEL trades at $11.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas RCEL's P/E ratio is -8.10. In terms of profitability, BIO's ROE is +0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BIO is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check RCEL's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while CATX trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas CATX's P/E ratio is -1.89. In terms of profitability, BIO's ROE is +0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BIO is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check CATX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while TLSI trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas TLSI's P/E ratio is -2.61. In terms of profitability, BIO's ROE is +0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BIO is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check TLSI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while INFU trades at $12.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas INFU's P/E ratio is 31.35. In terms of profitability, BIO's ROE is +0.03%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BIO is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for BIO.Check INFU's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BIO's ROE is +0.03%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, BIO is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BIO.Check MGRM's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ELMD trades at $28.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ELMD's P/E ratio is 21.51. In terms of profitability, BIO's ROE is +0.03%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BIO is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ELMD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BIO.Check NVRO's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while PROF trades at $5.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas PROF's P/E ratio is -6.04. In terms of profitability, BIO's ROE is +0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BIO is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BIO.Check PROF's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while RXST trades at $4.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas RXST's P/E ratio is -4.13. In terms of profitability, BIO's ROE is +0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BIO is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BIO.Check RXST's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO's ROE is +0.03%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, BIO is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check BSGM's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO's ROE is +0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BIO.Check MDGS's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while STIM trades at $2.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas STIM's P/E ratio is -5.81. In terms of profitability, BIO's ROE is +0.03%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BIO is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BIO.Check STIM's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while FOCL trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas FOCL's P/E ratio is -4.38. In terms of profitability, BIO's ROE is +0.03%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BIO is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BIO.Check FOCL's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while QTRX trades at $3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas QTRX's P/E ratio is -1.39. In terms of profitability, BIO's ROE is +0.03%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BIO is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BIO.Check QTRX's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO's ROE is +0.03%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, BIO is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BIO.Check QIPT's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while QSI trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas QSI's P/E ratio is -1.73. In terms of profitability, BIO's ROE is +0.03%, compared to QSI's ROE of -0.47%. Regarding short-term risk, BIO is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check QSI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while LUCD trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas LUCD's P/E ratio is -2.18. In terms of profitability, BIO's ROE is +0.03%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BIO is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BIO.Check LUCD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while INGN trades at $5.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas INGN's P/E ratio is -5.98. In terms of profitability, BIO's ROE is +0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BIO is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BIO.Check INGN's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO's ROE is +0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BIO is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ICAD's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ECOR trades at $11.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ECOR's P/E ratio is -6.57. In terms of profitability, BIO's ROE is +0.03%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, BIO is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for BIO.Check ECOR's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas HJLI's P/E ratio is N/A. In terms of profitability, BIO's ROE is +0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BIO is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BIO.Check HJLI's competition here

Bio-Rad Laboratories, Inc. (NYSE: BIO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIO stands at 10.2B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BIO is priced at $377.69 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIO currently has a P/E ratio of 40.70, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BIO's ROE is +0.03%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, BIO is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for BIO.Check ASXC's competition here